Franklin Genomic Advancements ETF (HELX)

Assets	$11.18M
Expense Ratio	0.50%
PE Ratio	32.31
Shares Out	400,000
Dividend (ttm)	n/a
Dividend Yield	n/a
Ex-Dividend Date	n/a
Payout Ratio	n/a
1-Year Return	-14.33%

Volume	2,860
Open	27.92
Previous Close	28.01
Day's Range	27.68 - 27.98
52-Week Low	27.68
52-Week High	33.98
Beta	1.09
Holdings	75
Inception Date	Feb 25, 2020

About HELX

Fund Home Page

The Franklin Genomic Advancements ETF (HELX) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed portfolio of global equity securities of companies relevant to genomic discovery. HELX was launched on Feb 25, 2020 and is issued by Franklin Templeton.

• Asset Class: Equity
• Category: Health
• Region: Global
• Stock Exchange: BATS
• Ticker Symbol: HELX
• ETF Provider: Franklin Templeton

Top 10 Holdings

39.18% of assets

Name	Symbol	Weight
Natera, Inc.	NTRA	5.30%
Krystal Biotech, Inc.	KRYS	5.11%
Vertex Pharmaceuticals Incorporated	VRTX	4.89%
Regeneron Pharmaceuticals, Inc.	REGN	4.14%
Samsung Biologics Co.,Ltd.	207940	3.77%
Medpace Holdings, Inc.	MEDP	3.64%
Eli Lilly and Company	LLY	3.38%
Thermo Fisher Scientific Inc.	TMO	3.37%
AstraZeneca PLC	AZN	2.93%
Corteva, Inc.	CTVA	2.65%